Trial · NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
NCT06387342, Phase 2, Recruiting, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Namodenoson Treatment of Advanced Pancreatic Cancer. Trials, record NCT06387342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06387342
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Namodenoson Treatment of Advanced Pancreatic Cancer
- NCT number
- NCT06387342
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- Namodenoson 25mg
- First posted
- 2024-04-29
- Last updated
- 2025-01-31
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | Every 2 weeks, assessed up to 1 year | Assessments of adverse events (AEs) will include characterization of type, incidence, severity (graded by CTCAE v5.0), seriousness, and relationship to treatment. |
| Primary | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline | Every 2 weeks, assessed up to 1 year | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), which is a scale of functioning, from 0 (normal activity) to 5 (death) |
| Secondary | Objective response rate | Every 8 weeks, assessed up to 1 year | clinical activity measure of objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI) |
| Secondary | Progression free survival | Every 8 weeks, assessed up to 1 year | clinical activity measure of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI) |
| Secondary | Disease control rate | Every 8 weeks, assessed up to 1 year | clinical activity measure of disease control rate (DCR) |
| Secondary | Duration of response | Every 8 weeks, assessed up to 1 year | clinical activity measure of duration of response (DoR), defined as the time from first response to disease progression or death from any cause, whichever occurs first |
| Secondary | Overall survival | Every 8 weeks, assessed up to 1 year | clinical activity measure of overall survival (OS), including death from any cause |
| Other | Quality of Life evaluation with EORTC QLQ-C30 | Every 4 weeks, assessed up to 1 year | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life |
| Other | Quality of Life evaluation with EORTC QLQ-PAN26 | Every 4 weeks, assessed up to 1 year | European Organization for Research and Treatment of Cancer Quality of Life pancreatic adenocarcinoma-specific module, the EORTC QLQ-PAN26, in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life |
| Other | Pharmacokinetics of namodenoson: Cmax | Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1 | Maximum plasma concentration of namodenoson |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06387342
GET https://conductscience.org/api/trials/v1/NCT06387342/registered